Search alternatives:
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 521 - 540 results of 163,154 for search '(( 2 a decrease ) OR ( 5 ((((wt decrease) OR (mean decrease))) OR (we decrease)) ))', query time: 2.00s Refine Results
  1. 521
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 522
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 523
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 524
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 525
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 526
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 527
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 528
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 529
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 530
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 531
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 532
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 533
    Quercetin decreases proliferation (A) and induces apoptosis (B) in cultured PASMC from control rats.

    Quercetin decreases proliferation (A) and induces apoptosis (B) in cultured PASMC from control rats. by Daniel Morales-Cano (668199)

    Published 2014
    Save to List
    Saved in:
  14. 534
    Chemical Inhibition of eEF1A-1 Peptide Elongation Activity Decreases Palmitate-Induced Cell Death.

    Chemical Inhibition of eEF1A-1 Peptide Elongation Activity Decreases Palmitate-Induced Cell Death. by Alexandra M. Stoianov (759321)

    Published 2015
    Save to List
    Saved in:
  15. 535
    DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte.

    DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

    Published 2020
    Save to List
    Saved in:
  16. 536
    MVEC viability is decreased over time in PEG-based hydrogels.

    MVEC viability is decreased over time in PEG-based hydrogels. by Rebecca A. Scott (488956)

    Published 2020
    Save to List
    Saved in:
  17. 537
    Western blot analysis of MPK-1 levels in WT and <i>let-60</i> mutants.

    Western blot analysis of MPK-1 levels in WT and <i>let-60</i> mutants. by Maximilian Kramer-Drauberg (8981141)

    Published 2020
    Save to List
    Saved in:
  18. 538
    CD11b and TLR-5 expression are decreased on CF macrophage membrane.

    CD11b and TLR-5 expression are decreased on CF macrophage membrane. by Karin Simonin-Le Jeune (464354)

    Published 2013
    Save to List
    Saved in:
  19. 539
    Ce6 decreases the amount of TMV PQS5 upon photo-irradiation.

    Ce6 decreases the amount of TMV PQS5 upon photo-irradiation. by Congbao Xie (17599247)

    Published 2023
    Save to List
    Saved in:
  20. 540
    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial

    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

    Published 2020
    Save to List
    Saved in:

Search Tools: